Sign up to save your podcasts
Or
Share What to Know about Sequel Med Tech's twiist AID System, with Alan Lotvin, MD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
What to Know about Sequel Med Tech's twiist AID System, with Alan Lotvin, MD
The diabetes community welcomed an additional tool to the armamentarium with the US Food and Drug Administration’s clearance of the twiist automated insulin delivery (AID) system on March 18, 2024. Cleared for use in patients aged 6 years and older with type 1 diabetes, the twiist, which is marketed by Sequel Med Tech, is billed as the first drug delivery system that directly measures volume and flow of inulin delivered with every micro-dose.
In this episode, Alan Lotvin, MD, co-founder and CEO of Sequel Med Tech, offers hosts a deep dive into the latest AID to receive approval, including the pump’s patient-centric design, why they chose to leverage the Tidepool Loop algorithm, plans for device launch, and more.
Chapters
00:00 - Start
01:00 - Lotvin Introduction
03:25 - Differences from Current AIDs
08:15 - Compatible CGMs
10:25 - Plans for Launch
12:05 - Design Discussion
16:50 - iPhone vs Android Compatibility
19:50 - Clinical Trials
22:20 - Tidepool Loop Algorithm
27:45 - Accuracy of Current Pumps
View all episodes
By Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
4.6
1010 ratings
The diabetes community welcomed an additional tool to the armamentarium with the US Food and Drug Administration’s clearance of the twiist automated insulin delivery (AID) system on March 18, 2024. Cleared for use in patients aged 6 years and older with type 1 diabetes, the twiist, which is marketed by Sequel Med Tech, is billed as the first drug delivery system that directly measures volume and flow of inulin delivered with every micro-dose.
In this episode, Alan Lotvin, MD, co-founder and CEO of Sequel Med Tech, offers hosts a deep dive into the latest AID to receive approval, including the pump’s patient-centric design, why they chose to leverage the Tidepool Loop algorithm, plans for device launch, and more.
Chapters
00:00 - Start
01:00 - Lotvin Introduction
03:25 - Differences from Current AIDs
08:15 - Compatible CGMs
10:25 - Plans for Launch
12:05 - Design Discussion
16:50 - iPhone vs Android Compatibility
19:50 - Clinical Trials
22:20 - Tidepool Loop Algorithm
27:45 - Accuracy of Current Pumps
More shows like Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
View all
NPR News Now
14,137 Listeners
Diabetes Core Update
97 Listeners
The Rich Roll Podcast
11,721 Listeners
Juicebox Podcast: Type 1 Diabetes
1,570 Listeners
Diabetes Connections | Type 1 Diabetes
217 Listeners
Hidden Brain
43,452 Listeners
AFP: American Family Physician Podcast
686 Listeners
The Curbsiders Internal Medicine Podcast
3,314 Listeners
Core IM | Internal Medicine Podcast
1,089 Listeners
The Peter Attia Drive
7,944 Listeners
Annals On Call Podcast
184 Listeners
The Huddle: Conversations with the Diabetes Care Team
37 Listeners
The Mel Robbins Podcast
20,846 Listeners
Diabetech - Diabetes Tech, Research, and News
38 Listeners
On The Pen With Dave Knapp
243 Listeners